Trastuzumab deruxtecan clinical trials
25 indexed studies · 15 currently recruiting
- Active not recruitingPHASE1, PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study looks at new drug combinations for metastatic triple-negative breast cancer. It combines standard treatment with new medicines (like Durvalumab) to see if they're safe and work well together for patients whose cancer has spread.
For: Triple Negative Breast NeoplasmsUnited States · Canada · Poland - Active not recruitingPHASE3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
This study looks at a new drug, trastuzumab deruxtecan, for people in the UK with HER2-positive stomach or food pipe cancer. It compares this drug to standard treatments for patients whose cancer has grown despite previous therapy. The aim is to see if the new drug works better and is safe.
For: Gastric Cancer, Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaArgentina · Belgium · Brazil - RecruitingPHASE3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
This study looks at new drug combinations for advanced or returning endometrial cancer that has a specific HER2 marker. It aims to see if these new treatments work better than standard chemotherapy by slowing down cancer growth.
For: Endometrial CancerUnited States · Australia · Austria - RecruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
For: Gastric Cancer · Gastroesophageal Junction CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study looks at a new drug, trastuzumab deruxtecan, for advanced breast cancer that is HER2-low and hormone receptor positive. We want to see if it works better and is safer than standard chemotherapy for people whose cancer has progressed after other treatments.
For: Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This study is looking at a new combination of medicines for a type of lung cancer that has spread or can’t be removed by surgery. It compares a drug called trastuzumab deruxtecan plus pembrolizumab to standard chemotherapy plus pembrolizumab.
For: Non-small Cell Lung CancerUnited States · Argentina · Belgium - RecruitingPHASE3
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This study looks at a new drug, Trastuzumab Deruxtecan, combined with an existing treatment, Bevacizumab, for a type of advanced ovarian cancer. It aims to see if this combination works better than Bevacizumab alone after initial chemotherapy.
For: Ovarian CancerUnited States · Australia · Austria - RecruitingPHASE1
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
This study is looking at a new medicine called LOXO-435 for cancers, especially bladder cancer, that have a specific gene change (FGFR3). It checks how safe and effective LOXO-435 is, both alone and with other standard treatments, to see if it can help patients.
For: Urinary Bladder Neoplasms · Neoplasm Metastasis · Ureteral NeoplasmsUnited States · Australia · Canada - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
For: Metastatic Breast CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
This study looks at new treatments for HER2-positive breast cancer that has spread. It compares an experimental drug, trastuzumab deruxtecan (T-DXd), alone or with another drug, pertuzumab, to standard care, to see if they work better and are safe.
For: Breast Cancer; HER2-positive; MetastaticUnited States · Argentina · Belgium - RecruitingPHASE3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
This study is looking at new treatments for advanced bile duct cancer that has a specific marker called HER2. We want to see if these new medicines work better and are safer than standard treatments for patients who haven't had treatment for their advanced cancer before.
For: Biliary Tract CancerUnited States · Australia · Austria - Active not recruitingPHASE2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
This study looks at a new treatment called trastuzumab deruxtecan (T-DXd) for several types of advanced cancer where a protein called HER2 is present. Researchers want to see how well it works and if it's safe for people with bladder, pancreatic, and other solid tumours.
For: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer · Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerUnited States · Australia · Belgium - RecruitingPHASE3
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
This study compares a new drug, trastuzumab deruxtecan, with standard chemotherapy for women with early-stage HER2-positive womb cancer. It aims to see which treatment works better after surgery to stop the cancer from coming back.
For: Endometrial CancerUnited States · Argentina · China - Recruiting
DESTINY Breast Respond HER2-low Europe
This study looks at a medicine called Trastuzumab deruxtecan (T-DXd) for advanced breast cancer that's HER2-low. It aims to understand how patients use it in real life, how well it works, and if they have any side effects, along with other chemotherapy options.
For: Unresectable Breast Cancer · Metastatic Breast Cancer · HER2-low Expressing Breast CancerAustria · Belgium · Denmark - RecruitingPHASE1, PHASE2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study looks at a new drug, zongertinib, for different HER2+ cancers that have spread. Researchers want to find the best dose, alone and with other treatments, to see if it can shrink tumours.
For: Metastatic Breast Cancer · Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Belgium · China - Active not recruitingPHASE3
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
This study looks at a new drug, trastuzumab deruxtecan, for people with a certain type of advanced lung cancer. It compares this new drug to standard treatments to see if it works better and is safe.
For: Locally Advanced or Metastatic Non-Small Cell Lung CancerUnited States · Austria · Belgium - Active not recruitingPHASE3
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
This study looks at a new treatment, Trastuzumab Deruxtecan (T-DXd), for advanced or metastatic HER2-positive breast cancer that has already been treated. It includes patients with or without brain metastases to see how safe and effective the treatment is.
For: Breast CancerUnited States · Australia · Belgium - RecruitingPHASE2
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
This study looks at a new drug, trastuzumab deruxtecan, for people with stomach or food pipe cancer that has a specific marker (HER2 positive) and has tiny traces of cancer DNA in their blood after surgery and chemotherapy. It aims to prevent the cancer from coming back.
For: Gastrooesophageal CancerUnited Kingdom - Active not recruitingPHASE2
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
This study looks at a new way to treat HER2-positive breast cancer that has come back locally or spread. It tests a two-step treatment: first, a medicine called T-DXd, followed by another medicine combo, PHESGO, to see how well they work.
For: HER2-positive Breast CancerUnited States · France · Germany - RecruitingPHASE3
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
This study looks at a new treatment, Trastuzumab-Deruxtecan, for some people with early breast cancer that has shown signs of coming back at a molecular level. It compares this new drug to standard treatments to see which works best.
For: Breast CancerGermany - RecruitingPHASE1
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Researchers are testing a new way to give a cancer drug called Trastuzumab Deruxtecan. Instead of a drip, they're giving it as an injection under the skin. This study aims to see if it's safe, works well, and if the body uses it in the same way, for people with advanced solid cancers.
For: Recurrent or Metastatic Solid TumorsUnited States · France · Japan